Cytx-investor.com

Saturday, 31 December 2011 15:50

Welcome to Cytx-Investor.com ^Featured

The page where you can find all relevant information about Cytori Therapeutics Inc, listed on Nasdaq- Symbol-CYTX. You can learn about its history, the people at Cytori and its disruptive technology. But primarily you can find here information on its broad therapeutic application platform by developing therapies with adipose derived regenerative cells (ADRC´s) against a whole range of presently unmet medical needs. This therapeutic application platform provides Cytori with a gigantic market potential, which is presently unfolding for anybody, that is willing to see it. Without a doubt the technology of Cytori will treat millions of patients in the nearby future...Read more

Thursday, 11 April 2013 00:00

Latest Editors Note

Written by Fas Kuiters (Profile)

The Epicenter of Medical Innovation
Last week-March 7 2013- Chris Calhoun - (still) Co-Founder, Vice Chairman, Chief Executive Officer, Secretary and Member of Executive Committee of Cytori concluded the business update and 4th quarter Conference Call with the following statement- For more than a decade, there's been much discussion around the hope and promise of regenerative medicine and Cell Therapy. Cytori is uniquely delivering on that promise today, improving the lives of thousands of patients around the world. With validation and support of key clinical…
Written on Friday, 15 March 2013 12:11Read more...

Friday, 12 April 2013 00:00

Latest Platform Item

Written by Fas Kuiters (Profile)

Bone-and connective tissue regeneration
Failure rates in healing of up to 30% are reported after fractures of the shoulder/ upper arm in elderly despite "locking" systems keeping the fractures stable. This may devastate not only the functional outcome, but also the independence of elderly patients. To increase bone mineral density and thereby holding-strength augmentation is an option. Autologous bone-graft, as current gold-standard, though is questionable in osteoporosis since osteoprogenitors are dysfunctional and the harvesting-morbidity considerable. Adipose tissue seems an alternative cell-source even in presence of…
Written on Wednesday, 30 January 2013 00:00Read more...

Thursday, 11 April 2013 22:06

Cytori´s Major News Releases

Written by Fas Kuiters (Profile)

Cytori´s most important Newsreleases
Of course- this selection is highly subjective, but as of to date I believe these to be ones that will have had the biggest impact of Cytori becoming a billion…
Read more...
09-2012 The BARDA Deal- access to US market
Cytori Awarded Contract Valued Up To $106 Million By Biomedical Advanced Research And Development Authority (BARDA) To Develop Cell Therapies For Thermal Burns Combined With Radiation Injury 09/28/2012 - Government…
Read more...
08-2012 Several CE mark marketing approvals
On August 9 2012 Cytori issued an announcement, which was a lot of irrelevant news except for one line "camouflaged" by a lot of other verbage-this line read: Cytori has expanded…
Read more...
2011-CYTX reports 18m APOLLO results
Cytori Reports Sustained Benefits at 18 Months in Cardiac Cell Therapy Heart Attack Trial SAN DIEGO, CA--(Marketwire - Jun 8, 2011) - Cytori Therapeutics is reporting 18 month outcomes from…
Read more...
2010-Cytori receives expanded device claims from EMA
Cytori Gains Stem Cell Device Approval in Europe for Breast Cancer Reconstruction and Soft Tissue Repair SAN DIEGO, Jul 27, 2010 (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ: CYTX) received expanded…
Read more...
2010-CYTX reports 18m PRECISE results
Adipose-Derived Regenerative Cells Improve Cardiac Functional Capacity at 18 Months in Chronic Ischemic Heart Disease Patients; Statistically Significant Improvement in MVO2 Reported by Cytori at American Heart Association SAN…
Read more...

Friday, 12 April 2013 12:24

Selected Editor Notes

Written by Fas Kuiters (Profile)

100% Hardcore-the power of the gimish
This article is 100% hardcore- rather technical, so really for the happy few with ambitions to understand all that jazz. On the other hand, the introduction and its message is provided in the first half, which is really very simple- i.e. fact is, that Cytori management has regarded its shareholders as "dumbo´s" for…
Written on Monday, 30 April 2012 15:52Read more...
Are the Olympus folks "visionary"?
Sometime in the early goings- 2007 or there abouts, when I still had my quarterly calls with CFO Mark Saad (which I later stopped since no value was added after an initial learning curve), I asked him the question whether he thought a partner deal in the bone regeneration field…
Written on Wednesday, 30 May 2012 17:16Read more...
Major Milestones achieved in the development of the Cytori application platform
...and hardly anybody realizes the above stated fact. The shareholders letter from Cytori, which was released on August 8 together with the Q2 numbers, contained some amazing lines, which apparently very few people have read sofar. These were the following- we are pleased to add new CE Mark indications-for-use based…
Written on Tuesday, 14 August 2012 11:57Read more...
Biding our time
Today- August 23 2012- a short while after the 2td quarter call and annual meeting webcast, investors, who a few weeks back were raging from anger, because of the non-execution of the promised pending partner deal in April, were converted back again into hopeful and confident investors, knowing that their…
Written on Tuesday, 21 August 2012 14:26Read more...
The Valley of Death- and Elephant Hunters theory re-visited
In January 2011 an excellent article appeared on Seeking Alpha written by John Petersen on the above theory- link here which I found very interesting and I believe applies to large degree also to Cytori. Key difference though is that CYTX innovation in addition to development also has to jump regulatory…
Written on Wednesday, 05 September 2012 15:00Read more...
The Biological Goldmine Confirmed
On January 8 2013 our beloved CEO Chris Calhoun made his "usual (?)" presentation at the Biotech Showcase conference in San Francisco. "Usual" since one could read afterwards from expert investors, that they did not hear anything new or special after listening to the webcast of the conference. To me…
Written on Wednesday, 09 January 2013 10:58Read more...
Mr.Dean- show me the money!
Dear Lloyd, I just checked my records-besides the usual mess, I could only find a statement from my bank dated somewhere in 2002, that my last purchase of MacroPore stock on the German exchange was made on September 20, 2001. The other purchases of my holdings at the time of…
Written on Friday, 08 February 2013 20:09Read more...

Friday, 12 April 2013 13:30

Editor´s favorite articles

Written by Fas Kuiters (Profile)

These articles are really my favorites- the first one brought me to the science and in respects of the other articles, I am proud to be the author of their content, although it does not bring me a dime.

Visions of the Future
In the earlier editions of CYTX-Investor.com I started this section with the visions of Prof. David Williams on regenerative medicine. Not that the visions of Prof. Williams will resemble exactly the past-, present- or future development of Cytori technology- could be , doesnt have to be though. His visions DO however, provide…
Written on Tuesday, 31 January 2012 21:00Read more...
Partner- Astellas Pharma Inc
Actually Astellas is of course a little more than just a candidate, since on December 7, 2010 they took an equity participation in Cytori, with the first right to negotiate a deal on liver regeneration. Cytori explained this in a note as follows: Such a partnership would likely revolve around…
Written on Monday, 09 April 2012 21:13Read more...
Mechanisms of Action of ADRCs
In the Wall Street press one always reads, when the theme "stem cells" comes up, what the difference in adult- and embryonic cell differentiation potential is and what these magic things all can do, or what they cant do. Words like pluripotency, multipotency and sometimes even the word progenitor cell…
Written on Friday, 03 February 2012 19:48Read more...
The versatility of Celution
There seem to be several misconceptions or maybe just different opinions about the ability for Cytori to protect the IP, which went into the designing- and engineering of the Celution range of products. Thereto different opinions about the technical superiority of the same system. I do not think the following…
Written on Saturday, 04 February 2012 19:34Read more...

Monday, 15 April 2013 18:54

Cytori- The Company- all articles

Written by Fas Kuiters (Profile)

Introduction to Cytori Therapeutics
Cytori´s Company slogan is: "Restoring Lives" - thereto its logo still displays the former slogan: "Where infinite possibilities meet" Both logo and slogan are really to my liking and I feel…
Written on Sunday, 01 January 2012 18:57Read 1399 times Read more...
Cytori´s history- untill 2005
Article- History untill 2005. Cytori became Cytori on July 11 2005 when the name change from MacroPore Biosurgery became official. Before that date, MacroPore obviously had some history too.…
Written on Monday, 09 January 2012 20:03Read 1233 times Read more...
Reflections on 11 years CYTX listing
MacroPore was from an investors viewpoint- kind of "the dark side" of Cytori- not only because of the failed Medtronic partnership on bio-resorbable implants, but also because of excessive option-plans and…
Written on Thursday, 12 January 2012 11:58Read 1199 times Read more...
The managers at Cytori
The management Team Of Cytori. The team is led by one of its Co-founders - Christopher J. Calhoun Chief Executive Officer Christopher J. Calhoun is a co-founder of…
Written on Sunday, 29 January 2012 18:58Read 1325 times Read more...
Cytori´s Board of Directors
First- some historical development- Untill 2007 Cytori´s Board of Directors was more of an "good ol boys" club, although by SEC rules considered " pre-dominantly independent". The father-in-law of CEO Calhoun…
Written on Monday, 30 January 2012 18:22Read 16670 times Read more...
Location & Mission
To conclude the first round of articles on Cytori- The Company, just an overview of the location from which the world of regenerative medicine will be conquered and what these folks who…
Written on Monday, 30 January 2012 23:17Read 961 times Read more...
Partner Olympus
Partner Olympus, as a Company, has major issues to resolve after the accounting cover-up scandal emerged. Dont want to comment that here, but you can read all about Woodford, Kikukawa…
Written on Wednesday, 29 February 2012 16:45Read 1032 times Read more...
Partner Roche
Second partner I would like to present here is Hoffmann La Roche- short -Roche. In the same conference call early 2009 when Calhoun talked about his partners, he described the proprietary enzyme…
Written on Saturday, 03 March 2012 00:13Read 1242 times Read more...
Partner- Astellas Pharma Inc
Actually Astellas is of course a little more than just a candidate, since on December 7, 2010 they took an equity participation in Cytori, with the first right to negotiate…
Written on Monday, 09 April 2012 21:13Read 945 times Read more...

Fas Kuiters

Just a short note to make you aware, that I have added a new "goody" to the site, which is the "social connect" feature, which you will find at the le...

Welcome to the Board and Blog ... in K2

about 1 week ago

In case you were wondering what this new image is all about, which you see when you enter the front page of the site and kind of is the introduction t...

Welcome to Cytx-Investor.com in K2

about 3 weeks ago

Hi- after doing a lot of work today in streamlining this site and ironing out glitches all over the place, I came to this article here after clicking ...

The Analyst´s view in K2

about 1 month ago

Guest (d9dozrman)

fas, your email to my yahoo account made me aware of your letter to Mr Dean, and brought me here. Very "eloquently" stated. My hope is that your lette...

Mr.Dean- show me the money! in K2

Guest (niorthe)

Thanks Fas for the article. In the last few days, I have increased my number of CYTX shares by 15%. In the past, i was waiting for some kind of positi...

The Biological Goldmine Confir... in K2